**Table S2:** Respiration and non-respiration inhibitors

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Inhibitor | mgL-1 | Plate media | Target(s) | Mitochondrial resistance mutations | Vendor |
| Nourseothricin | 4-5 | YPE | cytoplasmic/mitochondrial translation |  | Werner BioAgents |
| Paromomycin | 100-250 | YPE | cytoplasmic/mitochondrial translation | *15S\_RRNA* | Sigma-Aldrich |
| Hygromycin B | 30-55 | YPE | cytoplasmic/mitochondrial translation |  | Invitrogen (Thermo Fisher) |
| G418 | 15-20 | YPE | cytoplasmic/mitochondrial translation |  | Gibco (ThermoFisher) |
| Chloramphenicol | 50-100 | YPE and SE | mitochondrial translation | *21S\_RRNA* | Sigma-Aldrich |
| Erythromycin | 150-500 | YPE and SE | mitochondrial translation | *21S\_RRNA* | Sigma-Aldrich |
| Spiramycin | 250-500 | YPE and SE | mitochondrial translation | *21S\_RRNA* | Sigma-Aldrich |
| Oligomycin | 0.25-0.75 | YPE and SE | ATP synthase | *ATP6, OLI1* | Sigma-Aldrich |
| Antimycin A | 0.001-0.005 | YPE and SE | cytochrome bc1 | *COB* | Sigma-Aldrich |
| Myxothiazol | 0.05-0.1 | YPE and SE | cytochrome bc1 | *COB* | Sigma-Aldrich |
| Ethidium bromide | 0.5-1.5 | YPE and SE | mitochondrial DNA loss | ND | BioRad |
| Methotrexate | 5 | SE | mitochondrial DNA loss | ND | Sigma-Aldrich |
| 5-fluoro-uracil | 1 | SE | mitochondrial DNA loss | ND | Sigma-Aldrich |
| 5-fluoro-cytosine | 0.2 | SE | mitochondrial DNA loss | ND | Sigma-Aldrich |
| Cycloheximide | 0.25-0.5 | YPD and SD | Cytoplasmic translation | NA | Sigma-Aldrich |
| Ketoconazole | 10-20 | YPD and SD | Erg11; Ergosterol synthesis | NA | Sigma-Aldrich |
| Cupric sulfate  (copper) | 0.075-0.1mM | YPD and SD | Multiple | NA | Sigma-Aldrich |